# Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer

> **NCT01240941** · PHASE2 · WITHDRAWN · sponsor: **Vanderbilt-Ingram Cancer Center**

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** MK-2206
- **DRUG:** Exemestane
- **DRUG:** Goserelin

## Key facts

- **NCT ID:** NCT01240941
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-02
- **Primary completion:** 2012-06
- **Final completion:** 2012-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding was not available
- **Last updated:** 2013-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01240941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01240941, "Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01240941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*